EcoDrugPlus

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCHYG00000016565
Gene Symbol: PIM1
1 Cross references
248 Possible Orthologues:

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCHYG00000010311
Gene Symbol: PIM2
1 Cross references
115 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCHYG00000021161
Gene Symbol: PIM3
1 Cross references
196 Possible Orthologues:

Rar Related Orphan Receptor C

Ensembl ID : ENSCHYG00000005468
Gene Symbol: RORC
1 Cross references
383 Possible Orthologues:

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSCHYG00000004513
Gene Symbol: RELA
1 Cross references
200 Possible Orthologues:

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSCHYG00000021945
Gene Symbol: ROS1
1 Cross references
125 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCHYG00000025496
Gene Symbol: RAF1
1 Cross references
224 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSCHYG00000019635
Gene Symbol: ROCK1
1 Cross references
211 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSCHYG00000008822
Gene Symbol: ROCK2
1 Cross references
298 Possible Orthologues:

Sem1 26s Proteasome Subunit

Ensembl ID : ENSCHYG00000005072
Gene Symbol: SEM1
1 Cross references
156 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCHYG00000020614
Gene Symbol: SRC
1 Cross references
261 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSCHYG00000021500
Gene Symbol: TEK
1 Cross references
166 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).